Evidence map›Paper›PMID 35963508›Full record

GuidelineEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2022

American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

Lawrence Blonde, Guillermo E Umpierrez, S Sethu Reddy, Janet B McGill, Sarah L Berga, Michael Bush, Suchitra Chandrasekaran, Ralph A DeFronzo, Daniel Einhorn, Rodolfo J Galindo and 19 more

Erratum issued Registry-linked trialOpen access · greenAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06638099 (Increasing Use of Continuous Glucose Monitors Among Patients With Type 2 Diabetes), which is not on this map. Cited by 232 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
232citing papers in PubMed, 13 pooled it
59.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06638099 nacompletednot on this mapstarted 2024, after this paper: background citation

Increasing Use of Continuous Glucose Monitors Among Patients With Type 2 Diabetes

TypeinterventionalSponsorSan Diego State UniversityRan2024 to 2026Enrolled195ConditionsDiabetes, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus Type 2 (T2DM)ArmsCGM Toolkit Prescriber Training
3 · Its place in the literature

Who cites it

232 citing papers in PubMed, 13 syntheses or guidelines pooled it, 443 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

172 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 1 country.

Lawrence BlondeOchsner Health, New Orleans, Louisiana.
Guillermo E UmpierrezEmory University, Atlanta, Georgia.
S Sethu ReddyCentral Michigan University, Mount Pleasant, Michigan.
Janet B McGillWashington University in St. Louis, St. Louis, Missouri.
Sarah L BergaUniversity at Buffalo, Buffalo, New York.
Michael BushCedars-Sinai, Beverly Hills, California.
Suchitra ChandrasekaranEmory University, Atlanta, Georgia.
Ralph A DeFronzoUniversity of Texas, San Antonio, Texas.
Daniel EinhornScripps Whittier Diabetes Institute, La Jolla, California.
Rodolfo J GalindoEmory University, Atlanta, Georgia.
Thomas W GardnerUniversity of Michigan, Ann Arbor, Michigan.
Rajesh GargLundquist Institute/Harbor-UCLA Medical Center, Torrance, California.
W Timothy GarveyUniversity of Alabama at Birmingham, Birmingham, Alabama.
Irl B HirschUniversity of Washington, Seattle, Washington.
Daniel L HurleyMayo Clinic, Rochester, Minnesota.
Kenneth IzuoraUniversity of Nevada-Las Vegas, Las Vegas, Nevada.
Mikhail KosiborodSaint Luke's Mid America Heart Institute, Kansas City, Missouri.
Darin OlsonColorado Mountain Medical, LLC, Avon, Colorado.
Shailendra B PatelUniversity of Cincinnati Medical Center, Cincinnati, Ohio.
Rodica Pop-BusuiUniversity of Michigan, Ann Arbor, Michigan.
Archana R SadhuHouston Methodist; Weill Cornell Medicine; Texas A&M College of Medicine; Houston, Texas.
Susan L SamsonMayo Clinic, Jacksonville, Florida.
Carla StecAmerican Association of Clinical Endocrinology, Jacksonville, Florida.
William V TamborlaneYale School of Medicine, New Haven, Connecticut.
Katherine R TuttleUniversity of Washington and Providence Health Care, Seattle and Spokane, Washington.
Christine TwiningMaine Medical Center, Scarborough, Maine.
Adrian VellaMayo Clinic, Rochester, Minnesota.
Priyathama VellankiEmory University, Atlanta, Georgia.
Sandra L WeberUniversity of South Carolina School of Medicine-Greenville, Prisma Health System, Greenville, South Carolina.
Emory University · USMayo Clinic · USUniversity of Michigan–Ann Arbor · USAmerican Association of Clinical Endocrinologists · USCedars-Sinai Medical Center · USCentral Michigan University · USColorado Mountain College · USCornell University · USJacksonville College · USMaine Medical Center · USOchsner Health System · USPrisma Health · USProvidence Health & Services · USSaint Luke's Hospital · USScripps Whittier Diabetes Institute · USThe University of Texas at San Antonio · USUCLA Medical Center · USUniversity at Buffalo, State University of New York · USUniversity of Alabama at Birmingham · USUniversity of Cincinnati Medical Center · US

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI GERALD I SHULMAN · 1993 to 2026
$44.0M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
NIDDK Diabetic Foot Consortium Clinical Research UnitU01DK119083 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RODICA BUSUI (POP-BUSUI), Crystal Murray Holmes · 2018 to 2026
$5.5M
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2020 to 2024
$934k
Epigenetic Markers of Short- and Long- Term Near-Normoglycemia Remission in Patients with Ketosis-Prone DiabetesK23DK113241 · NIDDK · EMORY UNIVERSITY · PI VELLANKI, PRIYATHAMA · 2019 to 2021
$646k
NIDDK NIH HHS K23 DK113241NIDDK NIH HHS K23 DK123384NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK111024NIDDK NIH HHS U01 DK119083
6 · The paper itself

Abstract

objectiveThe objective of this clinical practice guideline is to provide updated and new evidence-based recommendations for the comprehensive care of persons with diabetes mellitus to clinicians, diabetes-care teams, other health care professionals and stakeholders, and individuals with diabetes and their caregivers.

methodsThe American Association of Clinical Endocrinology selected a task force of medical experts and staff who updated and assessed clinical questions and recommendations from the prior 2015 version of this guideline and conducted literature searches for relevant scientific papers published from January 1, 2015, through May 15, 2022. Selected studies from results of literature searches composed the evidence base to update 2015 recommendations as well as to develop new recommendations based on review of clinical evidence, current practice, expertise, and consensus, according to established American Association of Clinical Endocrinology protocol for guideline development.

resultsThis guideline includes 170 updated and new evidence-based clinical practice recommendations for the comprehensive care of persons with diabetes. Recommendations are divided into four sections: (1) screening, diagnosis, glycemic targets, and glycemic monitoring; (2) comorbidities and complications, including obesity and management with lifestyle, nutrition, and bariatric surgery, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic kidney disease, and cardiovascular disease; (3) management of prediabetes, type 2 diabetes with antihyperglycemic pharmacotherapy and glycemic targets, type 1 diabetes with insulin therapy, hypoglycemia, hospitalized persons, and women with diabetes in pregnancy; (4) education and new topics regarding diabetes and infertility, nutritional supplements, secondary diabetes, social determinants of health, and virtual care, as well as updated recommendations on cancer risk, nonpharmacologic components of pediatric care plans, depression, education and team approach, occupational risk, role of sleep medicine, and vaccinations in persons with diabetes.

conclusionsThis updated clinical practice guideline provides evidence-based recommendations to assist with person-centered, team-based clinical decision-making to improve the care of persons with diabetes mellitus.

Indexed as

Diabetes Mellitus, Type 2DyslipidemiasEndocrinologyChildFemaleHumansHypoglycemic AgentsInsulinPregnancyUnited StatesHypoglycemic AgentsInsulinantihyperglycemic medicationsatherosclerotic cardiovascular diseasecardiovascular diseasesdiabetesdiabetes mellitusdiabetes mellitus, type 1diabetes mellitus, type 2diabetic nephropathiesdiabetic neuropathiesdiabetic retinopathydyslipidemiasgestationalguidelinehospitalizationhypertensionhypoglycemiainfertilityinterdisciplinary communicationmetabolic syndromeobesityoccupationsprediabetic statepregnancysecondary diabetessleep apnea syndromestelemedicinevaccination

Identifiers

PMID35963508
PMCPMC10200071
OpenAlexW4291397630

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.